Indian Patent Office nixes HepC patent

Gilead Sciences charges $84,000 for their hepatitis treatment Sovaldi. They've worked out patent deals with a lot of countries - but India has denied them an Indian patent. The result: in India, generics will be legal, even for export. Interesting!